Zheng Wang

Zheng Wang

Auto-generated profile, based on publicly available information

Zheng Wang

Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, China; CAS Key Laboratory of Nano-Bio Interface, Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, 215123, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2022 in Journal of Materials Chemistry B
Verified
Journal Article
Open access
PDF file
WSWenqi Shen
Wenqi Shen
PYPing-An Yao
Ping-An Yao
WLWenjing Li
Wenjing Li
CGChangji Gu
Changji Gu
TGTian Gao
Tian Gao
CXchungen xing
chungen xing
Cancer-associated fibroblasts (CAFs) produce a critical tumor-promoting effect by cellular crosstalk with cancer cells and remodel the extracellular matrix (ECM) to form a protective physical barrier. The simple elimination of CAFs is not sufficient to govern the CAF-shaped aggressive tumor microenvironment (TME) because of the complexity of tumors. Herein, a CAF-targeted poly (lactic-co-glycolic acid) (PLGA) nanoemulsion is tailored to simultaneously deliver doxorubicin (DOX) and small interfering RNA (siRNA) targeting hepatocyte growth factor (HGF) for the combination of chemotherapy and gene therapy. The nanoemulsion (apt-Si/DNPs) shows a high specificity towards CAFs due to the aptamer modification and efficiently induces the apoptosis of CAFs, thus decreasing ECM deposition in the TME. Importantly, the delivered siRNA reduces the expression of the HGF in the remaining CAFs, which overcomes chemotherapy-induced upregulation of HGF mRNA and prevents the reproduction of CAFs through the autocrine HGF closed-loop. Owing to these synergetic effects, tumor proliferation, migration and invasion are prominently inhibited and tumor permeability is improved significantly. Overall, these results emphasize the potential of CAF-targeted combination treatments to inhibit tumor progression and metastasis, as well as overcome therapeutic resistance.

12 June 2024 in Advanced Science
Verified
Journal Article
Open access
CYChao Yang
Chao Yang
YCYinglu Chen
Yinglu Chen
JLJie Liu
Jie Liu
WZWensheng Zhang
Wensheng Zhang
YHYan He
Yan He
LWLiang Wang
Liang Wang
Senescent cancer cells are endowed with high immunogenic potential that has been leveraged to elicit antitumor immunity and potentially complement anticancer therapies. However, the efficacy of live senescent cancer cell‐based vaccination is limited by interference from immunosuppressive senescence‐associated secretory phenotype and pro‐tumorigenic capacity of senescent cells. Here, a senescent cancer cell‐based nanovaccine with strong immunogenicity and favorable potential for immunotherapy is reported. The biomimetic nanovaccine integrating a senescent cancer cell membrane‐coated nanoadjuvant outperforms living senescent cancer cells in enhancing dendritic cells (DCs) internalization, improving lymph node targeting, and enhancing immune responses. In contrast to nanovaccines generated from immunogenic cell death‐induced tumor cells, senescent nanovaccines facilitate DC maturation, eliciting superior antitumor protection and improving therapeutic outcomes in melanoma‐challenged mice with fewer side effects when combined with αPD‐1. The study suggests a versatile biomanufacturing approach to maximize immunogenic potential and minimize adverse effects of senescent cancer cell‐based vaccination and advances the design of biomimetic nanovaccines for cancer immunotherapy.

1 November 2024 in Science Advances
Verified
Journal Article
Open access
ZWZheng Wang
Zheng Wang
YCYinglu Chen
Yinglu Chen
HFHui Fang
Hui Fang
KXKai Xiao
Kai Xiao
ZWZiping Wu
Ziping Wu
DSDan Shao
Dan Shao
Harnessing the immunogenic potential of senescent tumor cells provides an opportunity to remodel tumor microenvironment (TME) and boost antitumor immunity. However, this potential needs to be sophisticatedly wielded to avoid additional immunosuppressive capacity of senescent cells. Our study shows that blocking the JAK2/STAT3 pathway enhances immunogenic efficacy of Aurora kinase inhibitor alisertib (Ali)–induced senescence by reducing immunosuppressive senescence-associated secretory phenotype (SASP) while preserving immunogenic SASP. Hypothesizing that SASP reprogramming with Ali and JAK2 inhibitor ruxolitinib (Rux) will benefit cancer immunotherapy, we create nanoparticulate crystals (Ali-Rux) composed of Ali and Rux with a fully active pharmaceutical ingredient. Immunization with Ali-Rux–orchestrated senescent cells promotes stronger activation of antigen-presenting cells, enhancing antitumor immune surveillance. This approach remodels the TME by increasing CD8 + T cell and NK recruitment and activation while decreasing MDSCs. Combined with PD-L1 blockade, Ali-Rux elicits a durable antitumor immune response, suggesting the TME reshaping approach as a potential cancer immunotherapy.

2 September 2023 in Biomaterials
Verified
Journal Article
Closed access
JLJunna Lu
Junna Lu
FCFangman Chen
Fangman Chen
XXXiaochun Xie
Xiaochun Xie
ZWZiping Wu
Ziping Wu
YCYinglu Chen
Yinglu Chen
RPRen-Jun Pei
Ren-Jun Pei

11 July 2023 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
ZYZiyi Yang
Ziyi Yang
YZYajie Zhang
Yajie Zhang
JWJine Wang
Jine Wang
JYJingbo Yin
Jingbo Yin
ZWZheng Wang
Zheng Wang
RPRen-Jun Pei
Ren-Jun Pei
The human cardiac organoid (hCO) is three-dimensional tissue model that is similar to an in vivo organ and has great potential on heart development biology, disease modeling, drug screening and regenerative medicine. However, the construction of hCO presents a unique challenge compared with other organoids such as the lung, small intestine, pancreas, liver. Since heart disease is the dominant cause of death and the treatment of such disease is one of the most unmet medical needs worldwide, developing technologies for the construction and application of hCO is a critical task for the scientific community. In this review, we discuss the current classification and construction methods of hCO. In addition, we describe its applications in drug screening, disease modeling, and regenerative medicine. Finally, we propose the limitations of the cardiac organoid and future research directions. A detailed understanding of hCO will provide ways to improve its construction and expand its applications.

3 May 2024 in Biomaterials
Verified
Journal Article
Closed access
SZShuting Zuo
Shuting Zuo
ZWZhenyu Wang
Zhenyu Wang
XJXiaoman Jiang
Xiaoman Jiang
YZYuewu Zhao
Yuewu Zhao
PWPanyue Wen
Panyue Wen
ZWZheng Wang
Zheng Wang